SENS Jan 2025 2.000 call
- PR Newswire
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
- Business Wire
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md., March 08, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes ("ATTD") in Florence, Italy.
- Business Wire
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md., March 06, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
